Clear cell cancer of the ovary

Current Opinion in Oncology

Volumn 25, Issue 5, 2013, Pages 553-557

  Penson, Richard T ^a   Dizon, Don S ^a   Birrer, Michael J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiogenesis; Clinical trials; Cytokines; Ovarian clear cell cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOKINE; DOXORUBICIN; GEMCITABINE; IRINOTECAN; PACLITAXEL; PEMETREXED; SCATTER FACTOR RECEPTOR; TEMSIROLIMUS; TOPOTECAN; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURGERY; CELL METABOLISM; CLEAR CELL CARCINOMA; CYTOREDUCTIVE SURGERY; ENDOMETRIOSIS; GENE AMPLIFICATION; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; OVARY CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ADENOCARCINOMA, CLEAR CELL; FEMALE; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; OVARIAN NEOPLASMS; PHYSIOLOGY; PROCEDURES;

ADENOCARCINOMA, CLEAR CELL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOKINES; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; OXIDATIVE STRESS;

EID: 84883238971     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328363e0c7     Document Type: Review

References (25)

1. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 2012; 460: 237-249. This is a complete review of all aspects of ovarian cancers. It integrates the molecular biology, pathology and clinical features of these tumors.
2. Del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol 2012; 126: 481-490. This is an excellent review of all recent literature relevant to clear cell cancers of the ovary.
3. Anglesio MS, Carey MS, Köbel M, et al. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 2011; 121: 407-415.
4. Stany MP, Vathipadiekal V, Ozbun L, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS ONE 2011; 6:e21121.
5. Takano M, Tsuda H, Sugiyama T. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment? J Exp Clin Cancer Res 2012; 31: 53. Nice summary of the issues and challenges in directing treatment by histology, rather than by origin of carcinoma.
6. Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology 2013; 45: 229-242. An excellent review directed at the pathology and potential precursor lesions for each type of ovarian cancer.
7. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012; 13: 385-394.
8. Worley MJ, Welch WR, Berkowitz RS, Ng S-W. Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci 2013; 14: 5367-5379.
9. Yanaihara N, Anglesio MS, Ochiai K, et al. Cytokine gene expression signature in ovarian clear cell carcinoma. Int J Oncol 2012; 41: 1094-1100.
10. Yamashita Y, Akatsuka S, Shinjo K, et al. Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. PLoS ONE 2013; 8:e57724.
11. Shigetomi H, Oonogi A, Tsunemi J, et al. The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary (Review). Oncol Lett 2011; 2: 591-597.
12. Birrer MJ. The origin of ovarian cancer - is it getting clearer? N Engl J Med 2010; 363: 1574-1575.
13. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
14. Tian C, Markman M, Zaino R, et al. CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer 2009; 115: 1395-1403.
15. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331-1338.
16. Takakura S, Takano M, Takahashi F, et al. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer 2010; 20: 240-247.
17. Japanese Gynecologic Oncology Group (JGOG) Ovarian Trial Protocol (version 3.1): Randomized phase III trial of paclitaxel plus carboplatin (TC) therapy versus irinotecan plus cisplatin (CPT-P) therapy as a first line chemotherapy for clear cell carcinoma of the ovary. Available at: . [Accessed 8 April 2013].
18. Hoskins PJ, Le N, Gilks B, et al. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J Clin Oncol 2012; 30: 1656-1662. This study summarizes the potential benefit of RT for patients with early-stage clear cell carcinoma.
19. Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20: 945-952.
20. Aghajanian C, Blank SV, Golf BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-2045.
21. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 3323-3329. doi: 10.1200/JCO.2009.25.7519.
22. Takano M, Ikeda Y, Kudoh K, et al. Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin. J Obstet Gynaecol Res 2012; 872-875. doi: 10.1111/j.1447-0756.2012. 02047.x.
23. Gordon MS, Vogelzang NJ, Schoffski P, et al. Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. J Clin Oncol 2011; 29:Suppl Abstr 3010.
24. Rahman M, Makayama K, Ishibashi T, et al. A case of stage iii c ovarian clear cell carcinoma: the role for predictive biomarkers and targeted therapies. Int J Mol Sci 2013; 14: 6067-6073.
25. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480: 480-489.